What is ISRG's DredgeCap risk score?

DredgeCap's AI analysis rates ISRG at 2.1/10 on the risk scale — Low risk. This score reflects dilution exposure, debt toxicity, liquidity position, and going-concern posture as disclosed in SEC filings.

Does ISRG have a going concern warning?

No current auditor going-concern warning is flagged in ISRG's SEC filings. Risk assessment is based on other filing-disclosed factors.

When did ISRG last file with the SEC?

ISRG's most recent SEC filing was a 10-K filed 2026-02-03. All filings are available on SEC EDGAR.

< Home

ISRG

Q: What does ISRG do?

Intuitive Surgical, Inc. (NASDAQ: ISRG) designs, manufactures, and markets robotic-assisted surgical systems, instruments, accessories, and services, with its da Vinci surgical system as its flagship platform. The company serves hospitals and surgical centers across domestic and international markets, generating revenue through system sales, instrument and accessory consumption, and service contracts. Its March 2026 acquisition of the da Vinci and Ion distribution business operated by ab medica and affiliates represents a recent expansion of its direct distribution footprint [Source: 8-K, filed 2026-03-02, Item 8.01].

Intuitive Surgical, Inc.

ISRG ⚖️Compare Forum

✅ Verdict

LOW RISK

No dominant structural financial risk is present; the primary risks worth monitoring for existing shareholders are external and competitive — specifically, regulatory scrutiny of medical device markets across multiple jurisdictions, competitive entry from alternative robotic surgery platforms, and execution risk around AI and machine learning integration into surgical systems, none of which presents an acute structural threat but any of which could affect the company's market position and pricing power over the medium term.

📉

Common Outcome:Sideways drift likely

⚠️

Secondary Risk:Elevated structural risks

🎯

Confidence:MODERATE

All risk signals are derived directly from SEC filings and supported by cited financial disclosures — not opinion or speculation.

ISRG Stock Risk Analysis

ISRG is a NASDAQ-listed stock with lower risk characteristics — a DredgeCap risk score of 2.1/10. No dominant structural financial risk is flagged in the most recent SEC filings; the primary considerations for existing shareholders are discussed in the analysis below, with supporting financial detail drawn from the 10-K and 10-Q.

Company Overview

Intuitive Surgical, Inc. (NASDAQ: ISRG) designs, manufactures, and markets robotic-assisted surgical systems, instruments, accessories, and services, with its da Vinci surgical system as its flagship platform. The company serves hospitals and surgical centers across domestic and international markets, generating revenue through system sales, instrument and accessory consumption, and service contracts. Its March 2026 acquisition of the da Vinci and Ion distribution business operated by ab medica and affiliates represents a recent expansion of its direct distribution footprint [Source: 8-K, filed 2026-03-02, Item 8.01].

AI-generated summary based on SEC filings. May contain errors. See disclosure

Investment Risk Score

BULLISH

2.1/10

LOW RISK

Dilution Risk

LOW1.5/10

Liquidity Risk

LOW1.2/10

Debt Toxicity

LOW1.3/10

Profitability Risk

LOW1.8/10

Premium Report

Full ISRG Stock Risk Report

The integrated analysis — primary risk driver in plain language, expected shareholder outcome, what would materially change the view, and what moves the stock. One-time $7.99, lifetime access for ISRG.

ISRG Risk Summary

⬤

Going Concern

No going concern warning

⬤

Accumulated Deficit

Not present in the provided source material; the balance sheet shows retained earnings of $7,011.8 million as of December 31, 2025, indicating no accumulated deficit position [Source: 10-K, filed 2026-02-03, Consolidated Balance Sheets].

⬤

Revenue

Strong Growth

⬤

Dilution

Shares outstanding declined slightly from 356.6 million as of December 31, 2024, to 355.1 million as of December 31, 2025, and to 354.9 million as of September 30, 2025, indicating a modest net reduction in share count over the period, consistent with share repurchase activity [Source: 10-K, filed 2026-02-03, Consolidated Balance Sheets; 10-Q, filed 2025-10-22, Condensed Consolidated Balance Sheets]. — None identified in the provided source material; no convertible notes, warrants, or other outstanding dilutive instruments are disclosed in the provided excerpts. Additional paid-in capital grew from $9,681.3 million to $10,768.5 million over fiscal year 2025, consistent with stock-based compensation activity, but no shareholder-adverse dilutive structures are present in the available material [Source: 10-K, filed 2026-02-03, Consolidated Balance Sheets].

Conclusion

Intuitive Surgical presents a strong financial profile characterized by growing revenue, substantial operating profitability, a clean balance sheet with no long-term debt visible in the provided source material, and a capital structure that appears shareholder-aligned with modest share count reduction over fiscal year 2025. The company's $2,806.6 million in cash and cash equivalents plus $5,625.9…

Premium Report

Unlock the full ISRG report

Plain-English dilution, debt, going-concern, and financials — every claim cited to a filing. One-time $7.99, lifetime access.

Dilution Analysis

Share count history & convertible note terms

View analysis →

Debt Structure

Loan terms, convertible notes & toxic debt

View analysis →

Going Concern

Auditor warnings & viability assessment

View analysis →

Full Financials

Revenue, income, balance sheet trends

View analysis →